BTIG Believes Hologic (HOLX) Won’t Stop Here


BTIG analyst Sean Lavin maintained a Buy rating on Hologic (HOLX) today and set a price target of $52. The company’s shares closed yesterday at $47.04, close to its 52-week high of $48.82.

According to TipRanks.com, Lavin is a 4-star analyst with an average return of 5.9% and a 53.3% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.

Currently, the analyst consensus on Hologic is a Moderate Buy with an average price target of $47.88, representing a 1.8% upside. In a report issued on April 2, Needham also maintained a Buy rating on the stock with a $50 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $48.82 and a one-year low of $35.10. Currently, Hologic has an average volume of 1.82M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts